France - MaaT Pharma (EURONEXT: MAAT the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.
Under the liquidity agreement entrusted by MaaT Pharma to Kepler Cheuvreux, the following resources were listed on the liquidity account on December 31st, 2023: 24,236 shares
EUR 34,107.60
Number of executions on buy side on semester: 627
Number of executions on sell side on semester: 368
Traded volume on buy side on semester: 18,328 shares for EUR 122,340.49
Traded volume on sell side on semester: 9,576 shares for EUR 64,693.03 As a reminder: the following resources appeared on the last half year statement on June 30, 2023 on the liquidity account: 15,484 shares
EUR 41,285.13
Number of executions on buy side on semester: 552
Number of executions on sell side on semester: 431
Traded volume on buy side on semester: 15,974 shares for EUR 144,745.75
Traded volume on sell side on semester: 12,997 shares for EUR 122,384.16
The following resources appeared on the liquidity account when the activity started: shares
EUR 200,000.00
The liquidity contract has been in effect since March 14, 2022, in accordance with the authorization granted by the General Meeting on March 3, 2022, and renewed on June 19, 2023. The implementation of this report is carried out in accordance with AMF Decision N-degree2021-01 of June 22, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris.
Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Contact:
Tel: 04 28 29 14 01
MAAT PHARMA 
